Benchmarks Nifty25,257.50113.21 Precious Metal Gold (MCX) (Rs/10g.)134,485.00-2220.0 Enter search text: Business News›Markets›Stocks›News Technical picks: ABB India among 5 stocks to buy this week for healthy returns Written by Akash Podishetti , ETMarkets.com| Nov 16, 2026, 09:51:08 AM IST 1/6 Add to cart Markets witnessed volatile yet positive trading during the truncated previous week, extending their winning streak to three consecutive weeks.

Sentiment remained constructive for most of the week, although profit booking on Friday trimmed the gains.

With the Q2 FY27 earnings season entering its final leg, investors will increasingly focus on macroeconomic developments and global cues.

Movements in crude oil, the dollar, US Treasury yields and FII flows will remain important determinants of market direction.

The stock has recovered from its recent lows and moved above the short-term moving average, indicating improving momentum.

RSI is rising toward the 60 level, supporting the positive price structure.

Immediate resistance is around Rs 4,450–Rs 4,500, while support lies near Rs 4,200–Rs 4,250.

Virat Jagad, Sr Technical Research Analyst, at Bonanza Portfolio ETMarkets.com 3/6 Buy ABB at Rs 7,050-7,055 | Stop Loss: Rs 6,767 | Target: Rs 7,614 ABB is showing a positive recovery, closing at Rs 7,054.50, up 1.90%, with price moving above its short-term moving average.

The stock has rebounded from recent lows near Rs 6,150 and is now testing a crucial resistance zone around Rs 7,050–Rs 7,150.

RSI is rising toward 60, indicating improving bullish momentum.

Immediate support is placed around Rs 6,850–Rs 6,900, followed by Rs 6,700.

Virat Jagad, Sr Technical Research Analyst, at Bonanza Portfolio Agencies 4/6 Buy Bank of Baroda at Rs 260 | Stop Loss: Rs 247 | Target: Rs 290 Bank of Baroda has shown a strong move above its major resistance level of 257 on the daily chart.

The breakout is supported by good volume, indicating increased buying interest and participation.

The stock has also sustained and closed above the 200-Day EMA, which reflects improvement in its overall price trend.

The Super trend indicator continues to show a bullish trend, suggesting that positive momentum remains intact.

Sachin Gupta, VP – Technical Research at Choice Equity Broking IANS 5/6 Buy NCC at Rs 131 | Stop Loss: Rs 125 | Target: Rs 145 NCC has moved out of its recent trading range on the daily chart, with rising volumes supporting the breakout.

The stock has also crossed above the upper Bollinger Band, indicating an improvement in price momentum.

Another important development is that it has sustained and closed above its 50-Day EMA, placed near 128.50, which now acts as an important level to watch.

The RSI has formed a bullish divergence and is currently trading at 60.60, reflecting a gradual improvement in buying strength.

Sachin Gupta, VP – Technical Research at Choice Equity Broking ETMarkets.com 6/6 Buy Mankind Pharma at Rs 2,668 | Stop Loss: Rs 2,535 | Target: Rs 2,940 Mankind Pharma has crossed its major resistance level of 2638 on the daily chart, with increasing volumes supporting the breakout.

This move indicates fresh buying interest and a possible continuation of the upward trend.

The stock is currently trading above all four key moving averages 21, 50, 100 and 200-Day EMAs which reflects strength across different timeframes.

Sachin Gupta, VP – Technical Research at Choice Equity Broking Disclosure: This article has been written by Podishetti Akash, who is not a SEBI-registered Research Analyst or an Investment Adviser.

Podishetti Akash and his ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication.

The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution.

They should not be construed as the views or recommendations of The Economic Times Digital or the journalist.

Readers are advised to consider the original research report and make their investment decisions based on their own assessment.

Brokerage disclosures here.